Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.45    0.00 (0.00%)
Bid:
8.30
Ask:
8.60
Spread: 0.30 (3.614%)
Market Cap: £18.43m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Re Agreement

26 Jun 2007 07:02

Phytopharm PLC26 June 2007 Company Contact: U.K. Investor Relations Contact:Phytopharm plc FDDr Daryl Rees CEO David YatesMr Piers Morgan CFO Ben Atwell+44 1480 437 697 +44 207 831 3113www.phytopharm.com Collaboration and Licence Agreement with The Beijing Institute for novel memoryand concentration product GODMANCHESTER, Cambridgeshire, U.K. (26 June 2007) - Phytopharm plc (LSE: PYM)("Phytopharm" or the "Company") announces today a Collaboration and LicenceAgreement with The Beijing Institute, Academy of Military Medical Sciences ("TheBeijing Institute") for the development of novel functional foods andpharmaceuticals, including a product for memory and concentration. Under the terms of the Collaboration and Licence Agreement, Phytopharm and TheBeijing Institute will collaborate to progress The Beijing Institute's leadproduct for memory and concentration selected from its library of patentedcompounds derived from Traditional Chinese Medicine. The Collaboration andLicence Agreement also extends to certain other patented compounds that may haveutility in other disease areas including vascular disorders and stroke.Phytopharm has been granted an exclusive licence from The Beijing Institute todevelop and commercialize these products globally in return for royalty andmilestone payments to The Beijing Institute upon the achievement of certainpre-defined goals. Financial terms of the agreement are not disclosed. Traditional Chinese Medicines have been used for thousands of years and overthat time a wealth of knowledge and expertise in the medicinal use of plants hasbuilt up. The Beijing Institute scientists have extensive knowledge ofTraditional Chinese Medicines and their research over the last 10 years has ledto the identification of a lead product that has the potential to improve memoryand concentration. Phytopharm will develop this lead product through furtherpre-clinical testing and progress into clinical trials. Commenting on today's announcement, Dr Xiaoming Yang, Head of The BeijingInstitute, said: "We are delighted to be working with Phytopharm and proud thatThe Beijing Institute's extensive expertise and experience in TraditionalChinese Medicine has been recognized by Phytopharm and we look forward to a longand fruitful collaboration." Commenting on today's announcement, Dr Daryl Rees, Chief Executive Officer ofPhytopharm, said: "We are excited about the Collaboration and Licence Agreementwith The Beijing Institute as it fulfils one of our strategic objectives ofexpanding our product portfolio with a novel functional food candidate formemory and concentration, an area in which we have established expertise. TheBeijing Institute's scientists bring significant knowledge on TraditionalChinese Medicine and we look forward to working with them to advance the leadproduct through clinical development." -Ends- Notes to Editors Phytopharm plc Phytopharm is a pharmaceutical development and functional food company whoseproduct leads are generated from medicinal plants. The Company's strategy is todevelop these products through 'proof of principle' clinical testing, and thensecure partners for late stage development, sales and marketing. Laboratory,manufacturing and clinical work is outsourced to selected specialists, operatingunder expert in-house management. This operational structure allows access tothe best external research facilities whilst maintaining low fixed overheads anda lower development cost structure. Beijing Institute The Beijing Institute (Institute of Radiation Medicine, the Academy of MilitaryMedical Sciences, Beijing) has over the past 50 years developed its researchstrengths from radiobiology into a wide range of scientific fields, includingbiotechnology, biochemistry, molecular biology, pharmaceutical chemistry,pharmacology, toxicology, experimental pathology, experimental haematology,genomics and proteomics. These groups were set up to provide the qualitycontrol for Traditional Chinese Medicine products and the identification anddevelopment of extracted active compounds. The Institutes considerableexpertise and experience in the extraction of active compounds from TraditionalChinese Medicine has resulted in several pharmaceutical products beingsuccessfully developed for the Chinese market. Functional Foods Functional foods are foodstuffs that provide health or physiological benefitsabove their nutritional value and have a health claim on the packaging.Currently gut and heart health products dominate with new interest in areas ofweight control, memory and concentration, immune system function and skinhealth. The global value of functional foods is estimated to be up to $65bn.The growth potential is predicted to be 50% from 2005-2010 with an acceleratingtrend for new products. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Jun 20077:00 amRNSBoard Change
14th Jun 20073:02 pmRNSResult of EGM
11th Jun 200711:56 amRNSHolding(s) in Company
7th Jun 200712:13 pmRNSDirector/PDMR Shareholding
5th Jun 20077:02 amRNSResearch Update
22nd May 20079:41 amRNSNotice of EGM
17th May 20077:01 amRNSResearch Update
9th May 20072:49 pmRNSDirector/PDMR Shareholding
9th May 20072:49 pmRNSDirector/PDMR Shareholding
9th May 20072:43 pmRNSDirector/PDMR Shareholding
9th May 20072:40 pmRNSDirector/PDMR Shareholding
1st May 20071:36 pmRNSBlocklisting Interim Review
1st May 20077:02 amRNSInterim Results
24th Apr 20074:37 pmRNSPrice Monitoring Extension
20th Apr 200711:26 amRNSNotice of Results
16th Apr 20077:01 amRNSProduct Launch
2nd Apr 20077:01 amRNSTotal Voting Rights
29th Mar 20079:36 amRNSResult of AGM
26th Mar 20077:12 amRNSProduct Launch
19th Mar 200711:45 amRNSBlocklisting Interim Review
7th Mar 20073:15 pmRNSHolding(s) in Company
7th Mar 20072:50 pmRNSHolding(s) in Company
2nd Mar 20072:25 pmRNSAGM Notification
1st Mar 20074:41 pmRNSSecond Price Monitoring Extn
1st Mar 20074:39 pmRNSPrice Monitoring Extension
1st Mar 20073:37 pmRNSPlacing
15th Jan 20074:36 pmRNSPrice Monitoring Extension
15th Jan 200712:52 pmRNSAnnual Information Update
10th Jan 20073:32 pmRNSDirector/PDMR Shareholding
10th Jan 20073:31 pmRNSDirector/PDMR Shareholding
9th Jan 200710:15 amRNSBoard Changes
19th Dec 200612:43 pmRNSTotal Voting Rights
10th Nov 20061:03 pmRNSDirector/PDMR Shareholding
8th Nov 20067:01 amRNSFinal Results
1st Nov 200612:58 pmRNSBlocklisting Interim Review
27th Oct 20063:02 pmRNSNotice of Results
18th Sep 20062:36 pmRNSBlocklisting Interim Review
5th Sep 20067:01 amRNSBoard Changes
21st Jul 20067:00 amRNSBoard Appointment
5th Jun 20067:00 amRNSAppointment of Non-Exec
19th May 20069:38 amRNSHolding(s) in Company
11th May 200610:37 amRNSDirector/PDMR Shareholding
11th May 200610:35 amRNSDirector/PDMR Shareholding
8th May 20067:02 amRNSInterim Results
3rd May 200612:32 pmRNSBlocklisting Interim Review
27th Apr 200611:33 amRNSHolding(s) in Company
27th Apr 200611:22 amRNSHolding(s) in Company
26th Apr 20067:01 amRNSAdvisor Appointment
24th Apr 20067:01 amRNSProduct Launch
10th Apr 20067:01 amRNSResearch Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.